A Critical Appraisal of Lc–Ms/Ms Bioanalytical Method Validation for Cilostazol According To USFDA and ICH M10
DOI:
https://doi.org/10.22270/ajprd.v14i2.1745Abstract
Cilostazol is a phosphodiesterase III inhibitor widely used for the treatment of intermittent claudication and prevention of thrombotic events. Accurate quantification of cilostazol in biological matrices is essential for pharmacokinetic evaluation, bioequivalence assessment, and therapeutic monitoring. Liquid chromatography coupled with tandem mass spectrometry has become the gold standard analytical technique due to its superior sensitivity, selectivity, and robustness. Regulatory authorities such as the United States Food and Drug Administration and the International Council for Harmonisation have established comprehensive guidelines to ensure reliability and reproducibility of bioanalytical data. The present review critically evaluates LC–MS/MS bioanalytical method validation for cilostazol with particular emphasis on regulatory expectations outlined in USFDA guidance and ICH M10. Method development strategies, validation parameters, matrix effects, stability considerations, incurred sample reanalysis, data integrity, and lifecycle management are discussed in depth. The article also highlights challenges encountered in real laboratory settings and provides perspectives on harmonization and future trends in bioanalytical science.
Downloads
References
Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, et al., Bioanalytical method validation—A revisit with a decade of progress, Pharmaceutical Research, 17, 12, 1551–1557.
U.S. Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry, FDA Guidance Document, 2018, NA, NA.
International Council for Harmonisation, Bioanalytical Method Validation M10 Guideline, ICH Harmonised Guideline, 2022, NA, NA.
Jemal M, Xia YQ, Bioanalytical method validation: A practical approach, Journal of Pharmaceutical and Biomedical Analysis, 32, 4–5, 797–805.
Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al., Quantitative bioanalytical methods validation and implementation, Pharmaceutical Research, 24, 10, 1962–1973.
European Medicines Agency, Guideline on bioanalytical method validation, EMA Guideline, 2011, NA, NA.
Xu RN, Fan L, Rieser MJ, El-Shourbagy TA, Recent advances in high-throughput quantitative bioanalysis by LC–MS/MS, Journal of Pharmaceutical and Biomedical Analysis, 44, 2, 342–355.
Jemal M, High throughput quantitative bioanalysis by LC–MS/MS, Biomedical Chromatography, 14, 6, 422–429.
Peters FT, Maurer HH, Bioanalytical method validation and its implications, Clinical Biochemistry, 35, 8, 603–614.
Cilostazol prescribing information, pharmacology and clinical data, Drug Information Journal, 45, 3, 215–223.
Matuszewski BK, Constanzer ML, Chavez-Eng CM, Matrix effect in quantitative LC–MS/MS analyses, Analytical Chemistry, 75, 13, 3019–3030.
Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR, Systematic and comprehensive strategy for reducing matrix effects, Journal of Chromatography B, 852, 1–2, 22–34.
Niessen WMA, Liquid chromatography-mass spectrometry fundamentals, Journal of Chromatography A, 1000, 1–2, 413–436.
Korfmacher WA, Principles and applications of LC–MS/MS in drug development, Drug Discovery Today, 10, 20, 1357–1367.
Jemal M, Quantitative determination of drugs using LC–MS/MS, Rapid Communications in Mass Spectrometry, 14, 6, 422–429.
Shabir GA, Validation of HPLC methods for pharmaceutical analysis, Journal of Chromatography A, 987, 1–2, 57–66.
Taylor PJ, Matrix effects: The Achilles heel of quantitative LC–MS/MS, Clinical Biochemistry, 38, 4, 328–334.
Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al., Fit-for-purpose method development, AAPS Journal, 8, 3, E580–E590.
Kostiainen R, Kauppila TJ, Effect of eluent on ionization in LC–MS, Journal of Chromatography A, 1216, 4, 685–699.
Jemal M, Ouyang Z, Chen BC, Teitz D, Quantitation of drugs in biological matrices, Journal of Chromatography B, 745, 1, 137–146.
FDA Reviewer Guidance on validation of chromatographic methods, FDA Guidance Document, 1994, NA, NA.
ICH Q2(R1), Validation of analytical procedures: Text and methodology, ICH Guideline, 2005, NA, NA.
Causon R, Validation of chromatographic methods, Journal of Chromatography B, 689, 1, 175–180.
Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD, Validation of bioanalytical methods, Analytica Chimica Acta, 391, 3, 247–259.
Jemal M, Schuster A, Whigan DB, LC–MS/MS bioanalysis challenges, Journal of Pharmaceutical Sciences, 92, 9, 1773–1784.
Chen Y, Chen B, Yao S, LC–MS/MS determination of cilostazol in plasma, Journal of Chromatography B, 879, 5–6, 367–372.
Zhang Y, Huo M, Zhou J, Xie S, LC–MS/MS quantification of cilostazol, Biomedical Chromatography, 23, 6, 627–632.
Zhou X, Zhang Q, Determination of cilostazol and metabolites, Journal of Pharmaceutical and Biomedical Analysis, 52, 4, 563–568.
Wang L, Li F, Bioanalysis of cardiovascular drugs, Journal of Chromatography B, 877, 5–6, 452–460.
Jemal M, Bioanalytical LC–MS/MS method development, Biomedical Chromatography, 14, 6, 422–429.
Cass QB, Degani AL, Enantioselective bioanalysis, Journal of Chromatography A, 1216, 21, 4603–4614.
Jemal M, Xia YQ, LC–MS/MS applications in drug development, Current Drug Metabolism, 7, 5, 491–502.
Niessen WMA, Progress in LC–MS instrumentation, Mass Spectrometry Reviews, 20, 6, 362–387.
Lee HS, Kim JH, LC–MS/MS assay validation, Journal of Pharmaceutical Investigation, 42, 2, 77–86.
FDA Guidance on pharmacokinetics, FDA Guidance Document, 2003, NA, NA.
European Medicines Agency, Bioequivalence guideline, EMA Guideline, 2010, NA, NA.
Matuszewski BK, Standard line slopes as measure of matrix effect, Analytical Chemistry, 75, 13, 3019–3030.
Jemal M, High-throughput bioanalysis, Journal of Pharmaceutical Sciences, 91, 5, 1299–1313.
Bansal S, DeStefano A, Key elements of bioanalytical validation, AAPS Journal, 9, 1, E109–E114.
Lee JW, Regulatory considerations for bioanalysis, Bioanalysis, 1, 3, 357–359.
Peters FT, Recent developments in LC–MS/MS bioanalysis, Clinical Biochemistry, 42, 13–14, 134–145.
Jemal M, Applications of LC–MS/MS in clinical pharmacology, Biomedical Chromatography, 16, 1, 1–12.
Xu RN, Applications of LC–MS/MS in drug metabolism studies, Journal of Pharmaceutical Sciences, 96, 5, 1237–1252.
Jemal M, Challenges in quantitative bioanalysis, Rapid Communications in Mass Spectrometry, 18, 7, 865–872.
Shah VP, Bioequivalence and bioanalytical considerations, Pharmaceutical Research, 18, 5, 589–592.
Midha KK, Rawson MJ, Hubbard JW, Bioanalytical issues in bioequivalence, Journal of Pharmaceutical Sciences, 82, 10, 969–980.
Jemal M, Recent trends in bioanalytical validation, Bioanalysis, 2, 1, 37–41.
Niessen WMA, Advances in mass spectrometry, Journal of Chromatography A, 1153, 1–2, 3–25.
Taylor PJ, Bioanalytical quality assurance, Clinical Biochemistry, 41, 7–8, 498–509.
Viswanathan CT, Workshop report on bioanalytical validation, Pharmaceutical Research, 24, 10, 1962–1973.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Srushti Chame, Shrikrishna Baokar, Rajendra Patil, Mansingh Rajput
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 